Reuters logo
BRIEF-Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​‍​
September 25, 2017 / 1:32 PM / 3 months ago

BRIEF-Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​‍​

Sept 25 (Reuters) - Shionogi & Co Ltd‍​

* Shionogi & Co Ltd - ‍ Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study​

* Shionogi & Co Ltd - ‍Lusutrombopag was generally well tolerated, with adverse events deemed treatment-related​

* Shionogi & Co Ltd - Lusutrombopag demonstrated superiority to placebo​

* Shionogi & Co - ‍based on results from l-plus1 and l-plus2 phase 3 studies, Shionogi has initiated rolling submission of a new drug application to FDA​

* Shionogi & Co Ltd - ‍Shionogi plans to present l-plus2 study data at future hepatology and hematology conferences later this year​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below